Fox Chase Cancer Center announce the hiring of Daniel Stapor, MD, as an Assistant Professor in the Department of Bone Marrow Transplant and Cellular Therapies. He will see patients at Fox Chase, Temple Health – Jeanes Campus, Temple Health – Chestnut Hill Hospital Campus and Temple University Hospital – Main Campus.
Stapor joins Fox Chase after completing its Hematology/Oncology Fellowship Training Program, where he was chief fellow. He brings to his new role a background in clinical research, cancer immunology and survivorship care, with a focus on lymphomas and adolescent and young adult oncology.
Stapor earned his medical degree from the Lewis Katz School of Medicine at Temple University and completed his internal medicine residency at the University of Pittsburgh Medical Center. He graduated with a bachelor’s degree in biology from Duke University, where he also minored in chemistry.
As a Fox Chase fellow, Stapor led and collaborated on numerous research initiatives, including retrospective and prospective clinical trials in hematologic malignancies and stem cell transplantation. He has presented nationally on topics such as early CAR-T therapy use, measurable residual disease-guided treatment in lymphoma and long-term outcomes in young adult patients post-transplant.
His research has been published in Genome Medicine, Blood and The American Journal of Clinical Pathology. In 2024, he received a Young Investigator Award from proceeds raised by In Vino Vita, Fox Chase’s signature fundraising event, to further his research on the effect of chemotherapy on the immune system for patients with non-Hodgkin lymphoma.
A member of the Alpha Omega Alpha Honor Medical Society, Stapor has earned multiple accolades, including the Western Pennsylvania ACP Resident Professionalism Award and the Thomas M. Durant Prize in Internal Medicine. His work bridges laboratory investigation and clinical application, with an emphasis on improving survivorship and quality of life for cancer patients.
Stapor began his tenure at Fox Chase on Sept. 1. ••
